DK Delek US posts blowout Q4 2025 EPS results far above estimates while shares dip 04 percent today Vertex Pharmaceuticals Incorporated VRTX Casgevy Commercial Momentum and Pipeline Catalysts Signal Upside Ahead of Partner CRISPR Therapeutics Q1 2026 Earnings VRM Vroom reports Q3 2025 earnings without prior analyst estimates stock rises 018 percent in daily trading